Efficacy And Safety Of Anti-interleukin-13 Monoclonal Antibodies In Treatment Of Moderate-to-severe Uncontrolled Asthma:a Meta-analysis

Objective:Using meta-analysis to systematically evaluate the efficacy and safety of anti-IL-13 monoclonal antibody in treatment of moderate to severe uncontrolled asthma,with a view to providing a reference for clinical medication.Methods:Literatures published before December 2019 about anti-IL-13 monoclonal antibodies in treatment of moderate-to-severe uncontrolled asthma were searched from PubMed,Embase,Cochrane Library,Web of Science,CNKI,Wanfang and VIP databases by computer,use the RCT quality assessment standards developed by Cochrane Network to conduct bias risk assessments for the inclusion of RCTs,and data were extracted to do meta-analysis using RevMan5.3 software.Results:Finally 8 RCTs from 6 articles were included,involved 5111 patients,3151 in anti-IL-13 monoclonal antibody group and 1960 in control group(placebo).Meta-analysis showed: compared with the control group,the anti-IL-13 monoclonal antibody group improved the forced expiratory volume in 1 second(MD=0.08,95%CI:0.06 to 0.10,P<0.000 01)and the Asthma Quality of Life Questionnaire score(MD=0.15,95%CI:0.10 to 0.19,P<0.000 01),reduced the Asthma Control Questionnaire score(MD=-0.10,95%CI:-0.15 to-0.05,P<0.000 1),incidence of acute exacerbation of asthma(MD=-0.19,95%CI:-0.32 to-0.06,P=0.005)and the use of emergency drugs(MD=-0.27,95%CI:-0.48 to-0.06,P=0.01).There was no significant difference in the incidence of overall adverse reactions(OR=1.16,95%CI:0.95 to 1.42,P=0.14),the incidence of serious adverse reactions(OR=0.87,95%CI:0.71 to 1.06,P=0.17)and the termination incidence of the trial due to adverse reactions(OR=1.60,95%CI:0.69 to 3.69,P=0.27)between the two groups.Conclusion:Anti-interleukin 13 monoclonal antibodies can improve lung function and life quality,reduce the incidence of acute exacerbation in patients with moderate-tosevere uncontrolled asthma,and is tolerated well.